Among the primary breast cancer patients of TCGA, the 4-gene score was higher in TNBC and HER2+ subtypes, which are known to be more clinically aggressive than HR+ and HER2− subtype (Figure 2). The gene discussed is ERBB2; the disease is breast carcinoma.